Skip to main content
HairCited

Deskripsi

Safety profile data for regenerative cellular therapies in alopecia clinical trials, documenting adverse events and tolerability outcomes.

Figure 11

Source Paper

Advancing Regenerative Cellular Therapies in Non-Scarring Alopecia.

Pharmaceutics (2022)

PMID: 35335987

DOI: 10.3390/pharmaceutics14030612

Cite This Figure

![Figure 11: Safety profile data for regenerative cellular therapies in alopecia clinical trials, documenting adverse events and tolerability outcomes.]()

> Source: Talagavadi Channaiah Anudeep et al. "Advancing Regenerative Cellular Therapies in Non-Scarring Alopecia.." *Pharmaceutics*, 2022. PMID: [35335987](https://pubmed.ncbi.nlm.nih.gov/35335987/)
<figure>
  <img src="" alt="Safety profile data for regenerative cellular therapies in alopecia clinical trials, documenting adverse events and tolerability outcomes." />
  <figcaption>Figure 11. Safety profile data for regenerative cellular therapies in alopecia clinical trials, documenting adverse events and tolerability outcomes.<br>  Source: Talagavadi Channaiah Anudeep et al. "Advancing Regenerative Cellular Therapies in Non-Scarring Alopecia.." <em>Pharmaceutics</em>, 2022. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35335987/">35335987</a></figcaption>
</figure>

Bukti Terkait

A
Minoxidil untuk Alopecia Androgenetik

Peringkat A · 299 studi

 A
Finasteride untuk Alopecia Androgenetik

Peringkat A · 206 studi

 A
Terapi PRP untuk Alopecia Areata

Peringkat A · 89 studi

 A
Minoxidil untuk Alopecia Areata

Peringkat A · 122 studi

 A
Terapi PRP untuk Alopecia Androgenetik

Peringkat A · 144 studi